Copyright
©The Author(s) 2015.
World J Gastroenterol. May 28, 2015; 21(20): 6236-6245
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Published online May 28, 2015. doi: 10.3748/wjg.v21.i20.6236
Figure 2 Association of patient survival and baseline fibrosis.
Five-year patient survival was superior in patients with low baseline fibrosis stage (P = 0.004). Blue curve: Patients with low baseline fibrosis stage; Red curve: Patients with moderate to advanced baseline fibrosis stage.
- Citation: Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World J Gastroenterol 2015; 21(20): 6236-6245
- URL: https://www.wjgnet.com/1007-9327/full/v21/i20/6236.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i20.6236